Innovative drugs promote precision cancer therapy

• DOI: 10.1007/s44272-023-00002-8
• Publication Date: 2023-12-06T00:02:10Z
• Authors: Xuan Huang; Mengxuan Zhu; Ruoxue Chen; Junjie Ni; Wenrui Zhao; Song Li; Xiaoling Lu; Heng Jiao; Xin Cao
• Keywords: 0301 basic medicine; 03 medical and health sciences

AbstractTargeted therapy has fundamentally altered the diagnosis and treatment of clinical cancers. By focusing on chromosomal abnormalities and various indications of cancer, these medications have paved the way for the precise treatment of malignant tumors. In addition to markedly reversing the status quo of reliance on radiotherapy, chemotherapy, and surgery, these drugs have radically transformed the clinical treatment of advanced malignant tumors and became the leading candidates in the fight against cancer. Significant advancements in new targeted medications, including small molecules (e.g., KRASG12C inhibitors), bispecific antibodies, antibody drug conjugates, and cellular immunotherapy, are due to the advent of new technology and treatments. Notably, numerous difficulties have been encountered, although each medicine class has its own unique benefits and drawbacks. To serve as a key summary for the development of new treatment options for precision cancer medicine recently, this review aimed to summarize the most recent anti-tumor revolutionary medications with significant prospective therapeutic advantages.